TrialCell reports. Medicine2025

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1.

Jean-Luc Van Laethem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.